Krystal Biotech Q1 2026 revenue $116.4M (+32% YoY); net income $55.9M; pipeline updates

Krystal Biotech, Inc.

2026-Q1 EPS reported $1.83 revenue$116,357,000

VYJUVEK global revenue $116.4M, up 32% YoY from $88.2M; gross margin 95%.
Net income $55.9M ($1.83 diluted EPS) vs $35.7M ($1.20) in Q1 2025; cash $1.0B.
FDA granted platform technology designation for KB407 (CF) and KB111 (HHD) program vectors.
KB803 (DEB corneal abrasions) fully enrolled; top-line data expected 4Q 2026. KB801 (NK) data before year end.
FY 2026 non-GAAP R&D+SG&A guidance $175-195M; KB407 open-label study starting, KB111 HALITE-1 initiating.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Krystal Biotech, Inc. reported first quarter ending March 31, 2026 results: revenue $116.4 million.

Period: first quarter ending March 31, 2026
Revenue: $116.4 million
Result: reported results

Exact text from the filing

Krystal Biotech Announces First Quarter 2026 Financial and Operating Results $116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Krystal Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001711279-26-000044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.